Company · Updated

What investors are saying about Merck & Co. (MRK)

ChorusBring the market's conversation to your AI. Learn more

Summary

In the past 90 days, 5 people on 5 investor and market shows discussed Merck & Co. (MRK) in 5 views. Going by each person's latest call, 3 are bullish and 2 bearish. Chorus has followed Merck & Co. since October 9, 2026.

Who talks about it most

Each person's latest call in the past 90 days, newest first. A call is what most of their views said that day; mixed when they were split. Every quote is checked against the episode's transcript.

Who's bearish on Merck & Co. (MRK) (2)

  • Chris Schott · J.P. MorganBearish

    Keytruda, the largest oncology launch, will likely be replaced by much better therapies in 5-7 years.

    Schott calls Keytruda the largest oncology product ever launched. He argues breakthroughs in newer technologies such as ADCs and bispecifics are improving standard of care in big tumor types like lung cancer, the largest cancer by incidence. He thinks there is a good chance Keytruda gets replaced within five to seven years by much better therapies. The bearish read for Merck is implied by this franchise-erosion argument rather than stated outright.

    “Keytruda, it's the largest oncology product ever launched. We think there's a good chance that that drug gets replaced in the next five or seven years with actually much better therapies.”at 3:44

    J.P. Morgan Making Sense: Healthcare’s next wave: AI, innovation and the future of access ·

  • Geoff Meacham · CitiBearish

    Merck faces a sell-the-news reaction; melanoma vaccine data were approvable but did not de-risk later trials.

    Merck's share of the Merck–Moderna melanoma vaccine data looked good and the drug looks approvable. However, investors expected the results to de-risk later kidney, bladder and lung cancer studies, and the results fell short. That produced a sell-the-news move, to a lesser degree in Merck than in Moderna.

    “The results didn't quite support that. And that's why you've seen a little bit of a sell the news phenom, definitely in Moderna and to a lesser degree Merck.”at 38:15

    CNBC Closing Bell: Closing Bell Overtime: Markets Face a Big Week as AI Takes Center Stage 10/26/26 ·

Who's bullish on Merck & Co. (MRK) (3)

  • Zach Reitano · RoBullish

    Merck's new oral PCSK9 could largely prevent heart disease if taken early enough.

    Zach describes a Dallas Heart Study finding that people with a naturally faulty PCSK9 gene had LDL in the 30s to 40s and an 85-90% lower risk of heart disease. Injectable PCSK9 drugs such as Repatha followed. He presents Merck's oral PCSK9 peptide, approved this year, as mimicking that faulty gene. He argues it could largely prevent heart disease, the leading US cause of death, if taken early, though he hedges with 'might'.

    “to invent an oral version that mimics that quote unquote faulty gene, but that if taken early enough might largely prevent and eliminate the leading cause of death in The US.”at 53:04

    Invest Like The Best: Zach Reitano - Building Ro and Why Healthcare Should Be 50% of GDP - [Invest Like the Best, EP.500] ·

  • Jim Cramer · CNBCBullish

    Merck is a terrific company; its strong run is due for consolidation, not a reason to sell.

    A caller who has held Merck for about twenty-one years, now 7% of the portfolio, asked whether to keep holding after volatility. Cramer says it is 100% a good hold and that CEO Rob Davis is doing a fantastic job. He says the stock rising from about $85 a year earlier to $148 should be expected to consolidate after such a climb, and he sees the company as a strong long-term holding.

    “I think Merck is a terrific stock and a great company.”at 10:28

    Mad Money with Jim Cramer: NVIDIA Risk, Anthropic IPO Test, and Texas Roadhouse Rally ·

  • Courtney Garcia · Payne Capital ManagementBullish

    Merck is the better trade on the cancer vaccine partnership: more diversified, without Moderna's extended move.

    Courtney says Moderna is up over 600% this year, so the move is already extended. Merck is part of the same NIH-linked cancer vaccine work, so if the two collaborate, Merck offers a much more diversified portfolio and hasn't had the same pop. She would take Merck for a trade.

    “look at Moderna, it's up over 600% this year... I would actually take a Merck here because if they are gonna work together, that is a much more diversified portfolio, and it doesn't have nearly the same pop it does.”at 21:53

    CNBC Fast Money: Trump strikes Russian diesel deal... And Apple’s latest iPhone woes 10/9/26 ·

Older views, and every view behind each call, are on the episode pages, and all of them are a question away in your AI with Chorus.

Ask your AI about Merck & Co. (MRK)

Chorus gives Claude, ChatGPT and other assistants every view on Merck & Co. (MRK) from the people Chorus follows. Ask who's bullish, who's bearish, who changed their mind, and why.

Chorus reports what speakers said. It isn't investment advice.